For the Inventor, By the Inventor

Enter assignee name

Hoersholm, Denmark

Santaris Pharma A/s

USPTO Granted Patents = 44

CIPO Patents = 3

EPO Patents = 18

Forward Citations = 1,572

Loading Chart...

Loading Chart...

78 inventors (with patents filed for the assignee):

Charlotte Albaek Thrue (11 out of 19 patents)

Majken Westergaard (10 out of 17 patents)

Troels Koch (9 out of 25 patents)

4. Henrik Frydenlund Hansen (8 out of 32 patents)

5. Christoph Rosenbohm (7 out of 17 patents)

6. Jesper Worm (7 out of 10 patents)

7. Daniel Sejer Pedersen (6 out of 12 patents)

8. Sakari Kauppinen (6 out of 26 patents)

9. Signe M Christensen (5 out of 10 patents)

10. Joacim Elmén (4 out of 10 patents)

11. Paul E G Kristjansen (4 out of 6 patents)

12. Jesper Wengel (4 out of 14 patents)

13. Margit Wissenbach (4 out of 4 patents)

14. Jens Bo Rode Hansen (4 out of 4 patents)

15. Frank Winther Rasmussen (3 out of 53 patents)

44 patents: Sort by Forward Citations

1. 9045518 - Amino-LNA, thio-LNA and alpha-L-oxy-LN (2015-06-02),

2. 9040493 - RNA antagonists targeting GLI2 for the treatment of leukemia (2015-05-26),

3. 8906871 - MicromiRs (2014-12-09),

4. 8785617 - Oligomeric compounds for the modulation of HIF-1A expression (2014-07-22),

5. RE44779 - Bicyclonucleoside and oligonucleotide analogues (2014-02-24),

6. 8653252 - Short interfering RNA (siRNA) analogues (2014-02-18),

7. 8580756 - Short oligomer antagonist compounds for the modulation of target mRNA (2013-11-12),

8. 8563528 - Antisense oligomers targeting PCSK9 (2013-10-22),

9. 8492390 - Synthesis of locked nucleic acid derivatives (2013-07-23),

10. 8492357 - Micro-RNA mediated modulation of colony stimulating factors (2013-07-23),

11. 8470791 - RNA antagonist compounds for the inhibition of Apo-B100 expression (2013-06-25),

12. 8450291 - RNA antagonist compounds for the modulation of PIK3CA expression (2013-05-28),

13. 8450290 - Methods for treating androgen receptor dependent disorders including cancers (2013-05-28),

14. 8440809 - RNA antagonists targeting Hsp27 (2013-05-14),

15. 8440637 - Combination treatment for the treatment of hepatitis C virus infection (2013-05-14),

Santaris Pharma A/S is a biopharmaceutical company specializing in the development of RNA-targeted therapies. With its focus on antisense oligonucleotide (ASO) technology, Santaris aims to create innovative treatments for various genetic and rare diseases. The company utilizes its proprietary platform to design and manufacture ASOs that can modulate the expression of specific disease-causing genes. Santaris Pharma is committed to advancing RNA-based therapeutics to improve the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

44 Patents

#2 in Hoersholm

#71 in Denmark

#15,270 in the World

Hoersholm, Denmark

Santaris Pharma A/s

Forward Citations = 1,572

78 inventors:

Charlotte Albaek Thrue (11 out of 19 patents)

Majken Westergaard (10 out of 17 patents)

Troels Koch (9 out of 25 patents)

4. Henrik Frydenlund Hansen (8 out of 32 patents)

5. Christoph Rosenbohm (7 out of 17 patents)

Please report any incorrect information to support@idiyas.com

Loading…